HR and breast cancer: Overall, these data show promising efficacy with fulvestrant plus palbociclib, with manageable adverse events.44 Based on these data, the FDA and European Union have approved the use of fulvestrant 500 mg for treating HR+/HER2− advanced or metastatic BC in combination with palbociclib in women with disease progression following endocrine therapy.66, 67